Merck & Co., Inc. (MRK) Shares Sold by Pinebridge Investments L.P.

Pinebridge Investments L.P. trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 3.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 529,121 shares of the company’s stock after selling 16,733 shares during the quarter. Merck & Co., Inc. makes up 0.8% of Pinebridge Investments L.P.’s holdings, making the stock its 20th biggest holding. Pinebridge Investments L.P.’s holdings in Merck & Co., Inc. were worth $29,774,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Merck & Co., Inc. by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock valued at $12,442,709,000 after purchasing an additional 3,312,459 shares during the last quarter. BlackRock Inc. grew its holdings in Merck & Co., Inc. by 1.0% during the 2nd quarter. BlackRock Inc. now owns 184,997,390 shares of the company’s stock valued at $11,856,484,000 after purchasing an additional 1,834,500 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in Merck & Co., Inc. by 7.5% during the 3rd quarter. Ameriprise Financial Inc. now owns 23,515,877 shares of the company’s stock valued at $1,505,621,000 after purchasing an additional 1,631,013 shares during the last quarter. Boston Partners grew its holdings in Merck & Co., Inc. by 0.8% during the 3rd quarter. Boston Partners now owns 18,730,874 shares of the company’s stock valued at $1,199,338,000 after purchasing an additional 145,744 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in Merck & Co., Inc. by 0.7% during the 3rd quarter. Legal & General Group Plc now owns 14,660,131 shares of the company’s stock valued at $938,669,000 after purchasing an additional 95,743 shares during the last quarter. Hedge funds and other institutional investors own 74.63% of the company’s stock.

Shares of MRK stock opened at $56.20 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.06 and a current ratio of 1.33. The stock has a market capitalization of $151,418.03, a price-to-earnings ratio of 14.12, a P/E/G ratio of 2.37 and a beta of 0.78. Merck & Co., Inc. has a one year low of $52.83 and a one year high of $66.41.



Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, February 2nd. The company reported $0.98 EPS for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.04. The business had revenue of $10.43 billion for the quarter, compared to the consensus estimate of $10.48 billion. Merck & Co., Inc. had a net margin of 6.40% and a return on equity of 28.61%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.89 EPS. equities analysts forecast that Merck & Co., Inc. will post 4.16 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, April 6th. Shareholders of record on Thursday, March 15th were paid a $0.48 dividend. The ex-dividend date of this dividend was Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a yield of 3.42%. Merck & Co., Inc.’s dividend payout ratio is currently 48.24%.

In other news, Director Wendell P. Weeks sold 5,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $53.57, for a total transaction of $267,850.00. Following the transaction, the director now directly owns 5,100 shares in the company, valued at $273,207. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Weir Mirian M. Graddick sold 60,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total transaction of $3,697,800.00. Following the transaction, the insider now owns 101,484 shares in the company, valued at $6,254,458.92. The disclosure for this sale can be found here. Insiders sold a total of 82,500 shares of company stock worth $5,026,025 over the last 90 days. Insiders own 0.25% of the company’s stock.

MRK has been the topic of several analyst reports. Barclays upgraded shares of Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $62.00 to $64.00 in a report on Thursday, April 5th. SunTrust Banks upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and upped their price target for the company from $54.00 to $72.00 in a report on Tuesday, January 16th. BMO Capital Markets set a $68.00 price target on shares of Merck & Co., Inc. and gave the company a “buy” rating in a report on Wednesday, December 13th. ValuEngine upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. Finally, DZ Bank upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the stock. Merck & Co., Inc. has an average rating of “Buy” and a consensus target price of $66.47.

COPYRIGHT VIOLATION WARNING: “Merck & Co., Inc. (MRK) Shares Sold by Pinebridge Investments L.P.” was originally reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/04/12/merck-co-inc-mrk-shares-sold-by-pinebridge-investments-l-p.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply